Antihistamines, Amantadine and Evolution of COVID-19
ConditionCOVID-19
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorConsorci Sanitari de Terrassa
About this trial
The rates of symptomatic COVID19 infection, hospital admission among COVID19 cases and survival would be quantified in patiens chronically treated with antihistamines or amantadine, with the aim of determining the role of antihistamines and amantadine in the evolution of COVID19.
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- Antihistamine
- Amantadine
Treatment groups
140,660 Participants
are divided into 2 treatment groupsSponsors and collaborators
Consorci Sanitari de Terrassa
Lead sponsor
Institut Català de la Salut
Collaborator
Source ClinicalTrials.gov